Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

A little over two decades ago, addressing Nigeria's HIV crisis topped U.S. President George W. Bush's priorities. Africa's most populous nation had 3.5 million HIV cases, and the disease threatened to ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are targeting the next goalpost: a cure.

There are several ways to address HIV in homeless populations, with the most promising being the low barrier care model, ...

The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy ...

The global HIV market is expected to reach $32.1 billion by 2033, driven by long-acting injectables and innovative therapies, ...

This makes Lenacapavir significantly more ... Sub-Saharan Africa Leads Global HIV Decline Nov. 25, 2024 — A new study reveals significant progress in the global fight against HIV/AIDS ...

Gilead Sciences’ long-acting drug to block HIV can end the AIDS epidemic worldwide. But accessibility is the question. © 2025 American City Business Journals. All ...

Announcing a new publication for Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Gilead Sciences’ long-acting drug to block HIV could end the AIDS epidemic worldwide. But access and funding remain big questions. Bay Area Biotech Forum The Future of Bay Area Biotech ...